Galera Therapeutics, Inc. (GRTX)の価格はいくらですか

Galera Therapeutics, Inc. (GRTX)の価格は$17.15です

Galera Therapeutics, Inc. (GRTX)の時価総額は何ですか

Galera Therapeutics, Inc. (GRTX)の時価総額は$6.51Mです

Galera Therapeutics, Inc.（GRTX）EPS（1株当たり利益）

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

年	EPS	変化
2026 (TTM)	$303.74	-86,882.86%
2024	$-0.35	-73.68%
2023	$-1.33	-42.17%
2022	$-2.30	-32.35%
2021	$-3.40	14.09%
2020	$-2.98	42.58%
2019	$-2.09	71.31%
2018	$-1.22	7,770.97%
2017	$-0.02	0.00%

年

EPS

変化

2026 (TTM)

$303.74

-86,882.86%

2024

$-0.35

-73.68%

2023

$-1.33

-42.17%

2022

$-2.30

-32.35%

2021

$-3.40

14.09%

2020

$-2.98

42.58%

2019

$-2.09

71.31%

2018

$-1.22

7,770.97%

2017

$-0.02

0.00%

企業	EPS	EPSの差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-94.30%	US
Argenx SE ARGX.US	$27.74	-90.87%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-95.49%	BE

企業

EPS

EPSの差

国